JP2013532153A5 - - Google Patents

Info

Publication number

JP2013532153A5

JP2013532153A5 JP2013515507A JP2013515507A JP2013532153A5 JP 2013532153 A5 JP2013532153 A5 JP 2013532153A5 JP 2013515507 A JP2013515507 A JP 2013515507A JP 2013515507 A JP2013515507 A JP 2013515507A JP 2013532153 A5 JP2013532153 A5 JP 2013532153A5

Authority

JP

Japan

Prior art keywords

polypeptide agent

tim

ligand interaction

seq

site

Prior art date

2011-06-16

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Withdrawn

Links

• Espacenet
• Global Dossier
• Discuss

• 239000003795 chemical substances by application Substances 0.000 claims description 44
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 44
• 229920001184 polypeptide Polymers 0.000 claims description 42
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 42
• 230000003993 interaction Effects 0.000 claims description 40
• 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 28
• 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 28
• 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 28
• 239000003446 ligand Substances 0.000 claims description 28
• 230000027455 binding Effects 0.000 claims description 14
• 125000000539 amino acid group Chemical group 0.000 claims description 12
• 230000001684 chronic effect Effects 0.000 claims description 12
• 208000026278 immune system disease Diseases 0.000 claims description 12
• 230000009870 specific binding Effects 0.000 claims description 12
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 9
• 210000001744 T-lymphocyte Anatomy 0.000 claims description 8
• 150000001413 amino acids Chemical class 0.000 claims description 8
• TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 4
• 108010074708 B7-H1 Antigen Proteins 0.000 claims description 4
• 102100031351 Galectin-9 Human genes 0.000 claims description 4
• 101710121810 Galectin-9 Proteins 0.000 claims description 4
• ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 4
• 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 4
• 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 4
• 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 4
• 206010028980 Neoplasm Diseases 0.000 claims description 4
• 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 4
• 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 4
• 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 4
• 208000037581 Persistent Infection Diseases 0.000 claims description 2
• 230000003213 activating effect Effects 0.000 claims description 2
• 201000011510 cancer Diseases 0.000 claims description 2
• 230000028993 immune response Effects 0.000 claims description 2
• 239000008194 pharmaceutical composition Substances 0.000 claims 6
• 102000001708 Protein Isoforms Human genes 0.000 claims 2
• 108010029485 Protein Isoforms Proteins 0.000 claims 2
• 210000004027 cell Anatomy 0.000 description 11
• 238000000034 method Methods 0.000 description 6
• 102000004127 Cytokines Human genes 0.000 description 4
• 108090000695 Cytokines Proteins 0.000 description 4
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
• 230000004044 response Effects 0.000 description 4
• 108010002350 Interleukin-2 Proteins 0.000 description 3
• 108091008874 T cell receptors Proteins 0.000 description 3
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
• 230000003013 cytotoxicity Effects 0.000 description 3
• 231100000135 cytotoxicity Toxicity 0.000 description 3
• 230000000638 stimulation Effects 0.000 description 3
• -1 IFNγ Proteins 0.000 description 2
• 102000003814 Interleukin-10 Human genes 0.000 description 2
• 108090000174 Interleukin-10 Proteins 0.000 description 2
• 102000013691 Interleukin-17 Human genes 0.000 description 2
• 108050003558 Interleukin-17 Proteins 0.000 description 2
• 102000004388 Interleukin-4 Human genes 0.000 description 2
• 108090000978 Interleukin-4 Proteins 0.000 description 2
• 108091008035 T cell costimulatory receptors Proteins 0.000 description 2
• 239000002458 cell surface marker Substances 0.000 description 2
• 230000000694 effects Effects 0.000 description 2
• 108091008875 B cell receptors Proteins 0.000 description 1
• 108010002616 Interleukin-5 Proteins 0.000 description 1
• 102000000743 Interleukin-5 Human genes 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 210000004970 cd4 cell Anatomy 0.000 description 1
• 230000009743 cell cycle entry Effects 0.000 description 1
• 230000032823 cell division Effects 0.000 description 1
• 108091008034 costimulatory receptors Proteins 0.000 description 1
• 230000016396 cytokine production Effects 0.000 description 1
• 210000002443 helper t lymphocyte Anatomy 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• 108020003175 receptors Proteins 0.000 description 1